{"entity":{"id":"nct06384807","kind":"trial","name":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Cemiplimab in advanced solid tumours, run by Biohaven Therapeutics Ltd., now recruiting.","summary":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors. ClinicalTrials.gov record last updated 2026-09-28: recruiting. Enrollment is planned at 500 participants. Primary completion is estimated at 2028-02. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: BHV-1510, Cemiplimab, BHV-1510, BHV-1510, Cemiplimab. Registered primary measures: Phase 1: Number of patients with adverse events (AEs); Phase 1: Recommended doses or schedules for expansion (RDEs) and maximum tolerated dose (MTD); Phase 2: Objective Response Rate (ORR) for BHV-1510 for monotherapy and in combination with cemiplimab.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06384807","url":"https://clinicaltrials.gov/study/NCT06384807"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["trop2"],"drugs":["cemiplimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-09-28: recruiting. Enrollment is planned at 500 participants. Primary completion is estimated at 2028-02. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06384807","phase":"1/2","setting":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors","sponsor":"Biohaven Therapeutics Ltd.","participation":[{"nct":"NCT06384807","source":"https://clinicaltrials.gov/study/NCT06384807","fetchedAt":"2026-10-07T16:54:36.402Z","studySha256":"048aa0f4e4f10a70e3a84f2f606f2523050cdea4a2e22f7292300e896f11ac73","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-28","leadSponsor":"Biohaven Therapeutics Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":500,"enrolmentType":"ESTIMATED","siteCount":17,"recruitingSiteCount":16,"countries":["United States"]}],"started":"2024-04-22","startedType":"actual","enrolled":500,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06384807/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"bhv-1510","kind":"drug","name":"BHV-1510","route":"/drugs/bhv-1510/"},{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"}]}}